Tinea Unguium Management

Last updated: 23 April 2026
Reviewed by

Principles of Therapy

The treatment for onychomycosis is indicated in patients experiencing pain or discomfort related to the infected nails, in patients with diabetes and other risk factors for cellulitis, in patients with a history of ipsilateral lower extremity cellulitis, in immunosuppressed patients, to prevent the spread of fungal infection to other parts of the body (eg feet, hands, groin) and to close contacts, and for cosmetic reasons.

Patients with confirmed onychomycosis but are refractory to treatment may benefit from switching to an alternative oral agent. Topical and systemic antifungal agents constitute primary treatments. Factors influencing the choice between topical and systemic therapy include the clinical subtype, causative organism, disease severity, potential side effects, the feasibility of monitoring for adverse effects, treatment availability, and cost. Topical therapy offers the advantage of minimal risk for serious adverse effects or drug interactions compared with systemic agents, but it usually requires longer treatment durations and may be less effective, especially in extensive disease or when the nail matrix and lunula are involved.

Disease severity guides the choice of therapy for dermatophyte onychomycosis. For mild to moderate cases (eg distal lateral subungual onychomycosis affecting ≤50% of the nail and sparing the matrix/lunula), both systemic and topical treatments are reasonable options. Systemic therapy is preferred for more severe disease (eg involvement of >50% of the nail, matrix or lunula involvement, proximal subungual onychomycosis, or total dystrophic onychomycosis). White superficial onychomycosis is often adequately managed with topical therapy alone because the infection is confined to the nail surface.

Pharmacological therapy

Oral Antifungals

Fluconazole



Tinea Unguium_Management 1Tinea Unguium_Management 1




Fluconazole is active against common dermatophytes, Candida sp and some non-dermatophytic molds. This offers an alternative to Itraconazole and Terbinafine. This is not approved in most countries for onychomycosis treatment. Fluconazole is fungistatic, and high-dose pulse therapy for fingernail treatment has been shown to have up to a 90% clinical cure rate with near-total mycologic elimination. Outcome data on toenail treatment shows clinical improvement in 72-89% of patients treated.

Griseofulvin

Griseofulvin may be used as an alternative oral antifungal for onychomycosis. There is similar efficacy with azole antifungals. The disadvantage of Griseofulvin is the need for a prolonged treatment course.

Itraconazole

Itraconazole is a first-line agent for treatment of mild to moderate dermatophyte onychomycosis and second-line therapy for patients with severe dermatophyte onychomycosis who cannot tolerate oral Terbinafine. This has broad antifungal coverage that includes dermatophytes, Candida sp and a number of non-dermatophyte molds. This is fungistatic, and the mycologic cure rates range from 45-70% and clinical cure rates from 35-80%. Studies have shown that both continuous and pulse therapies are effective.

Posaconazole

Posaconazole is a newer, broadspectrum oral antifungal agent that may be effective for treating onychomycosis. This may be used as an alternative oral antifungal for onychomycosis. A major disadvantage of posaconazole is its high cost, which supports the preference for other systemic treatment options.

Terbinafine 



Tinea Unguium_Management 2Tinea Unguium_Management 2




Terbinafine is a first-line agent for the treatment of mild to moderate to severe dermatophyte onychomycosis. This is active against dermatophytes, which are the cause of the majority of onychomycosis infections. This is not as active against Candida sp or non-dermatophyte molds. The effect of terbinafine is fungicidal, and the mycotic cure rate for toenails is 71-82% and the clinical cure rate is 60-70%. Some comparative trials have shown Terbinafine to be more effective than other agents for onychomycosis treatment.

Topical Antifungals

Topical antifungals are limited to mild cases involving very distal nail plates and to those unable to tolerate systemic treatment. There is a low response rate because of poor nail plate penetration. This is used as an adjunct to oral therapy for resistant infections and may be used in combination with surgical nail avulsion.

Amorolfine

Amorolfine is active against dermatophytes, dimorphic fungi, yeasts, and other filamentous and dematiaceous fungi. This may be effective in patients with mild infection without nail matrix (lunula) involvement. This has been used in combination with oral Terbinafine or Itraconazole. Combination therapy may be useful for patients with severe onychomycosis.

Ciclopirox

Ciclopirox is a hydroxypyridone-based agent effective against dermatophytes, yeasts, and molds. This is indicated in mild-to-moderate distal superficial onychomycosis. Treatment may take 6 months-1 year and cure rates range from 29-47%.

Efinaconazole

Efinaconazole is a triazole antifungal developed for the treatment of mild to moderate distal lateral subungual onychomycosis (DLSO). This inhibits fungal lanosterol 14α-demethylase, involved in the biosynthesis of ergosterol. This is indicated for onychomycosis of the toenails due to T rubrum or T mentagrophytes.

Luliconazole

Luliconazole is an imidazole molecule with fungicidal and fungistatic activity. This may be used as treatment for moderate to severe DLSO caused by T rubrum or E floccosum.

Tavaborole

Tavaborole is a lightweight, water-soluble oxaborole topical nail lacquer (boron-containing compound). This is indicated for onychomycosis of the toenails due to T rubrum or T mentagrophytes.

Tioconazole

Tioconazole is a treatment option for superficial and distal onychomycosis.

Indications for Extended Duration of Use

Indications for extended duration use of antifungals include patients whose nails grow slowly, patients who have decreased blood supply to the nail as a result of conditions (eg peripheral vascular occlusion, DM), and patients who have near-total or total nail plate involvement.

Other Treatment Options

Antifungal Nail Polish



Tinea Unguium_Management 3Tinea Unguium_Management 3




Antifungal nail polish is indicated for mild to moderate nail infections, with a maximum of 40% of the total nail surface affected and/or a maximum of 3/10 toenails affected. In a trial, Amorolfine 5% nail lacquer demonstrated an increase of healthy nail surface by 13% after weekly application for 180 days.

Topical Urea

Topical urea is a keratolytic agent used to reduce the infected and hyperkeratotic nail material. This is recommended as an adjunctive therapy combined with systemic antifungal treatment.   

Nonpharmacological

Patient Education



Tinea Unguium_Management 4Tinea Unguium_Management 4




Educate the patient about proper foot hygiene. Patients should wear breathable footwear and 100% cotton socks. Change socks often, if possible. Keep feet dry throughout the day; may use antifungal foot powder. Recognize and treat tinea pedis to prevent spreading to the toenails.

Patients should be encouraged to maintain and improve health conditions (eg regularly trim nails short, control DM, quit smoking, exercise, etc). Assure the patient that improvement continues even after cessation of oral treatment since the fungus is continually exposed to the medication secondary to the drug’s binding to keratin in the nail, though recurrence is common. This may take 9-12 months to assess the cure.

Other Treatment Options

Further studies are needed to prove the safety and efficacy of the following management options for tinea unguium.

Laser Therapy



Tinea Unguium_Management 5Tinea Unguium_Management 5




Neodymium-doped:yttrium-aluminum-garnet (Nd:YAG) and dual-wavelength (870 and 930 nm) near-infrared diode lasers are newer treatment options that showed significant improvements in nail appearance in several studies when used together with topical antifungal agents.

Photodynamic Therapy (PDT)

Photodynamic therapy involves the use of photosensitizing agents and a light source to treat fungal infection.

Alternative Therapies

Examples of alternative therapies are Ageratina pichinchensis (snakeroot) extract, Melaleuca alternifolia (tea tree) oil, and menthol. These may help with symptom relief, but further studies are needed to establish the therapeutic benefit of these agents. 

Surgery

Surgical Avulsion and Debridement



Tinea Unguium_Management 6Tinea Unguium_Management 6




Surgical avulsion may be considered for patients with single-nail onychomycosis unresponsive to pharmacological agents alone, followed by topical antifungal therapy. Debridement may be considered as an adjunct to topical or oral pharmacologic interventions.